Vivek Samal, MD

ILiAD Biotechnologies
Weston, Florida, United States

Disclosure(s): No financial relationships to disclose

Presentation(s):

• 596 - Immunogenicity and Safety of BPZE1, an Intranasal Live Attenuated Pertussis Vaccine, Evaluated With and Without Tdap in Healthy Children 6 to 17 Years Old: A Phase 2b, Randomized, Active-Controlled Study

  Saturday, October 19, 2024
  2:45 PM – 3:00 PM US PT